RFCA
CBPO

R&F Capital Advisors’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

R&F Capital Advisors’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$422K Sell
4,218
-1,040
-20% -$111K 0.11% 300
2016
Q4 		$565K Buy
+5,258
New +$615K 0.2% 154

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
HIM
Hermes Investment Management London Uk, United Kingdom $7.52B AUM 20.67% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

R&F Capital Advisors's CBPO Position: Q1 2017 in Review

R&F Capital Advisors reduced its China Biologic Products Holdings, Inc. (CBPO) stake by 20% in Q1 2017, selling an estimated $111K and leaving 4,218 shares worth $422K. The position accounts for 0.11% of the portfolio, ranked #300.

R&F Capital Advisors first reported a position in CBPO in Q4 2016 and has held it in 2 quarters since. The position peaked at $565K in Q4 2016. 136 funds tracked by Wall St. Rank hold CBPO as of Q1 2017.

  • R&F Capital Advisors held 4,218 shares of China Biologic Products Holdings, Inc. worth $422K as of Q1 2017.
  • R&F Capital Advisors sold 1,040 China Biologic Products Holdings, Inc. shares in Q1 2017, an estimated $111K.
  • China Biologic Products Holdings, Inc. made up 0.11% of R&F Capital Advisors's portfolio in Q1 2017, its #300 holding.
  • R&F Capital Advisors first reported a position in China Biologic Products Holdings, Inc. in Q4 2016 and has held it in 2 quarters since.
  • R&F Capital Advisors's China Biologic Products Holdings, Inc. position peaked at $565K in Q4 2016.
  • 136 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.